The conversation about GLP-1 treatment is moving beyond how much weight people lose at the start. Another question matters just as much: what happens during the next stage? Research available in October 2026 gives us more information about maintaining weight reduction with tirzepatide.
The study started after an initial treatment period
In a 2026 maintenance trial, adults first received tirzepatide for 60 weeks. Researchers then randomly assigned 378 participants to continue their maximum tolerated study dose, move to a lower study dose, or switch to placebo for another 52 weeks.
Continuing the maximum tolerated dose maintained more weight reduction on average than the other approaches. The lower-dose group also had better average weight outcomes than the placebo group. Individual responses varied.
The details limit what we can conclude
Participants had already completed a long initial treatment period, so the results don’t describe everyone starting medicine. The study also allowed rescue treatment later for substantial regain. That feature matters when interpreting the final averages.
These findings support a discussion about ongoing care; they don’t establish a do-it-yourself dose-reduction schedule. They also shouldn’t be assumed to apply identically to every GLP-1 medicine or formulation.
What to ask at a maintenance visit
You can bring three practical questions: Is the current plan still helping my health? Am I eating and functioning well? What would lead us to change the approach?
Discuss symptoms, strength, food intake, cost, and access alongside weight trends. If you’re considering a change, ask how it will be monitored and when you should contact the team. Get the actual instructions in writing rather than adapting a study protocol yourself.
Keep the daily support in place
Whatever the medicine plan, a workable routine still matters. Keep dependable meals, appropriate activity, and follow-up that fits your life. If the routines need to change as appetite or circumstances change, ask for help adjusting them.
New research can make those conversations more informed without providing one answer for everyone. Maintenance deserves the same attention as starting treatment: a clear plan, a way to measure how you’re doing, and people you can reach when the plan needs another look.